Clinigen Group plc Directorate Change (3169T)
March 24 2021 - 04:00AM
UK Regulatory
TIDMCLIN
RNS Number : 3169T
Clinigen Group plc
24 March 2021
24th March 2021
Clinigen appoints Sharon Curran as independent Non-Executive
Director
Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global
pharmaceutical Products and Services company, has appointed Sharon
Curran as a new independent Non-Executive Director, effective from
27 April 2021.
Sharon is an experienced non-executive board director as well as
having proven top-level experience in leading high impact global
marketing, commercialisation and growth strategies for world class
pharmaceutical corporations (AbbVie, Abbott Pharmaceuticals and Eli
Lilly).
She is currently a Non-Executive Director for Circassia Group
plc where she is Chair of the Remuneration Committee. She is also
on the Board of Morphosys AG (Audit & Risk Committee). Before
taking these roles, she was VP, Global Marketing and Commercial
Operations at AbbVie where she worked from 2012 to 2017. Whilst
there, she was on the ethics & compliance committee, involved
in portfolio strategy and was part of the global crisis management
team. Previously, she was Global Brand and Regional Commercial
Director at Abbott Pharmaceuticals (2009-2012) and before then, she
was Divisional Head, Strategy & Operations (Ireland & UK
Affiliate) for Eli Lilly (1999-2008). She has a MSc in Business
Administration from Trinity College, Dublin and a B.Sc in
Biotechnology from Dublin City University. She has a Chartered
Director Program Diploma from the Institute of Directors.
Peter Allen, Chairman of Clinigen, said:
"One area of focus for Clinigen over the past 12 months has been
to bring new expertise onto the Board from industry and from other
company boards. We are fortunate with Sharon that she has an equal
measure of both. She has worked for multinational companies in the
US and Europe, both in active executive positions as well as senior
advisory on ethics and compliance, portfolio strategy and global
crisis management. She has gone on to develop a broad portfolio of
non-executive director roles with a variety of European companies.
She is a welcome addition to the Clinigen Board and we look forward
to her joining in April."
The following information is disclosed pursuant to AIM Rule 17
and Schedule Two paragraph (g) of the AIM Rules for Companies
Sharon Evelyn Curran , aged 52 years, is currently a director of
the following companies:
Current directorships
* C ircassia Group plc
* Morphosys AG
* CAT Capital BidCo Ltd
* CAT Capital TopCo Ltd
There is no further information to be disclosed pursuant to AIM
Rule 17 and Schedule Two paragraph (g) of the AIM Rules for
Companies.
- Ends -
Contact details
Clinigen Group plc Tel: +44 (0) 1283 495010
Shaun Chilton, Chief Executive Officer Investors@Clinigen.com
Nick Keher, Chief Financial Officer
Numis Securities Limited - Nominated Adviser Tel: +44 (0) 20 7260 1000
& Joint Broker
James Black / Garry Levin / Freddie Barnfield Clinigen @Numis.com
RBC Capital Markets - Joint Broker Tel: +44 (0) 20 7653 4000
Marcus Jackson / Elliot Thomas
Instinctif Partners Tel: +44 (0) 20 7457 2020
Melanie Toyne-Sewell / Tim Linacre / Rozi Morris
/ Phillip Marriage clinigen@instinctif.com
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global, specialist
pharmaceutical services and products platform focused on providing
ethical access to medicines. Its mission is to deliver the right
medicine to the right patient at the right time. The Group operates
from sites in North America, Europe, Africa and the Asia
Pacific.
Clinigen has more than 1,250 employees across five continents in
16 countries, with supply and distribution hubs and operational
centres of excellence in key long-term growth regions. The Group
works with 34 of the top 50 pharmaceutical companies; interacting
with over 5,000 hospitals across more than 115 countries.
For more information on Clinigen, please visit
http://www.clinigen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAGIGDXXSDDGBS
(END) Dow Jones Newswires
March 24, 2021 05:00 ET (09:00 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From Mar 2023 to Mar 2024